Blood cells: an historical account of the roles of purinergic signalling

Purinergic Signalling

Volumn 11, Issue 4, 2015, Pages 411-434

  Burnstock, Geoffrey ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adenosine; ADP; Clopidogrel; Erythrocytes; P2X1; P2Y12; P2Y1; Platelets; Purinoceptor; Thrombosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; ISOPRENALINE; LEUKOTOXIN; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; SURAMIN; ADENOSINE DIPHOSPHATE; PURINERGIC RECEPTOR;

BLOOD CELL; ERYTHROCYTE; GENE EXPRESSION; HUMAN; LEUKOCYTE; MEGAKARYOCYTE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PURINERGIC SIGNALLING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; ANIMAL; BLOOD; METABOLISM; PHYSIOLOGY;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; BLOOD CELLS; BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION; RECEPTORS, PURINERGIC; SIGNAL TRANSDUCTION;

EID: 84947617394     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-015-9462-7     Document Type: Review

References (404)

1. Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509–581
2. Burnstock G (1978) A basis for distinguishing two types of purinergic receptor. In: Straub RW, Bolis L (eds) Cell membrane receptors for drugs and hormones: a multidisciplinary approach. Raven Press, New York, pp 107–118
3. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492
4. Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci 64:1471–1483
5. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, Torboli M, Bolognesi G, Baricordi OR (2001) Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97:587–600
6. Wolff R (1947) Etude de lacide adenosine-triphosphorique dans le sang du lapin. C R Seances Soc Biol Fil 141:665–667
7. Nakao M, Nakao T, Yamazoe S, Yoshikawa H (1961) Adenosine triphosphate and shape of erythrocytes. J Biochem 49:487–492
8. Feo C, Mohandas N (1977) Clarification of role of ATP in red-cell morphology and function. Nature 265:166–168
9. Knull HR, Bronstein WW, Porter PJ (1978) Adenosine triphosphate and diphosphoglycerate levels in red blood cells from patients with Down’s syndrome. Experientia 34:1133–1134
10. Dern RJ, Brewer GJ, Wiorkowski JJ (1967) Studies on the preservation of human blood. II. The relationship of erythrocyte adenosine triphosphate levels and other in vitro measures to red cell storageability. J Lab Clin Med 69:968–978
11. Parker JC (1970) Metabolism of external adenine nucleotides by human red blood cells. Am J Physiol 218:1568–1574
12. Quist EE, Roufogalis BD (1977) Association of (Ca + Mg)-ATPase activity with ATP-dependent Ca uptake in vesicles prepared from human erythrocytes. J Supramol Struct 6:375–381
13. 2+, ATP, and protein activator. J Supramol Struct 10:215–225
14. 2+)-ATPase of human red cell membranes with low affinity for Mg-ATP: a hypothesis for its function. FEBS Lett 111:269–271
15. Lichtman MA (1975) Does ATP decrease exponentially during red cell aging? Nouv Rev Fr Hematol 15:625–632
16. Parker JC, Snow RL (1972) Influence of external ATP on permeability and metabolism of dog red blood cells. Am J Physiol 223:888–893
17. Elford BC (1975) Interactions between temperature and tonicity on cation transport in dog red cells. J Physiol 246:371–395
18. Romualdez A, Volpi M, Sha’afi RI (1976) Effect of exogenous ATP on sodium transport in mammalian red cells. J Cell Physiol 87:297–305
19. Parker JC, Castranova V, Goldfinger JM (1977) Dog red blood cells: Na and K diffusion potentials with extracellular ATP. J Gen Physiol 69:417–430
20. 2+. Arch Biochem Biophys 203:123–133
21. Patel VP, Fairbanks G (1986) Relationship of major phosphorylation reactions and MgATPase activities to ATP-dependent shape change of human erythrocyte membranes. J Biol Chem 261:3170–3177
22. 2+-ATPase activity in red blood cell membranes. Eur J Biochem 243:58–65
23. + channels and muscarinic and purinergic receptors identified in human erythroid progenitor cells and red blood cell ghosts. Proc Natl Acad Sci U S A 101:12370–12374
24. Downes CP, Berrie CP, Hawkins PT, Stephens L, Boyer JL, Harden TK (1988) Receptor and G-protein-dependent regulation of turkey erythrocyte phosphoinositidase C. Philos Trans R Soc Lond B Biol Sci 320:267–280
25. 2Y purinergic receptor agonists and guanine nucleotides. J Biol Chem 264:884–890
26. 2y-purinergic receptors. Biochem J 284:917–922
27. 2y purinoceptors. Mol Pharmacol 35:526–532
28. 1 receptor: pharmacological, signaling, and molecular properties. Drug Dev Res 39:253–261
29. 1 purinoceptors expressed in turkey erythrocytes? Neurosci Lett 293:78–80
30. Light DB, Capes TL, Gronau RT, Adler MR (1999) Extracellular ATP stimulates volume decrease in Necturus red blood cells. Am J Physiol 277:C480–C491
31. Light DB, Dahlstrom PK, Gronau RT, Baumann NL (2001) Extracellular ATP activates a P2 receptor in necturus erythrocytes during hypotonic swelling. J Membr Biol 182:193–202
32. 7 receptor. J Biol Chem 279:44749–44755
33. 2+] in the red blood cells of the lizard Ameiva ameiva (Squamata, Teiidae). Braz J Med Biol Res 38:5–10
34. 2+ reveals a functional membrane nucleotide pool in intact human red blood cells. J Gen Physiol 138:381–391
35. 7 receptor activation causes phosphatidylserine exposure in human erythrocytes. Biochem Biophys Res Commun 355:169–173
36. 7 receptor induces the release of epoxyeicosatrienoic acids. Br J Pharmacol 151:1033–1040
37. Jiang H, Anderson GD, McGiff JC (2010) Red blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP). Pharmacol Rep 62:468–474
38. 7 receptor: greatly increased function compared with human erythrocytes. Am J Physiol Regul Integr Comp Physiol 293:R2090–R2098
39. 7 receptor mediates the uptake of organic cations in canine erythrocytes and mononuclear leukocytes: comparison to equivalent human cell types. Purinergic Signal 5:385–394
40. Bontemps F, Van den Berghe G, Hers HG (1988) 5'-Nucleotidase activities in human erythrocytes. Identification of a purine 5'-nucleotidase stimulated by ATP and glycerate 2,3-bisphosphate. Biochem J 250:687–696
41. 1 receptor triggers two calcium signaling pathways in bone marrow erythroblasts. Eur J Pharmacol 534:30–38
42. Kostic MM, Mojsilovic LP, Zivkovic RV (1981) Effect of adenosine on glycolysis in human red-blood-cells. Ircs Med Sci-Biochem 9:186–187
43. Braun S, Levitzki A (1979) Adenosine receptor permanently coupled to turkey erythrocyte adenylate cyclase. Biochemistry 18:2134–2138
44. Porsche E (1982) Effects of methylxanthine derivatives on the adenosine uptake in human-erythrocytes. Ircs Med Sci-Biochem 10:389
45. Plagemann PG, Wohlhueter RM, Kraupp M (1985) Adenosine uptake, transport, and metabolism in human erythrocytes. J Cell Physiol 125:330–336
46. Franco R, Aran JM, Colomer D, Matutes E, Vives-Corrons JL (1990) Association of adenosine deaminase with erythrocyte and platelet plasma membrane: an immunological study using light and electron microscopy. J Histochem Cytochem 38:653–658
47. Baumann R, Blass C, Götz R, Dragon S (1999) Ontogeny of catecholamine and adenosine receptor-mediated cAMP signaling of embryonic red blood cells: role of cGMP-inhibited phosphodiesterase 3 and hemoglobin. Blood 94:4314–4320
48. Niemoeller OM, Bentzen PJ, Lang E, Lang F (2007) Adenosine protects against suicidal erythrocyte death. Pflugers Arch 454:427–439
49. Pafundo DE, Alvarez CL, Krumschnabel G, Schwarzbaum PJ (2010) A volume regulatory response can be triggered by nucleosides in human erythrocytes, a perfect osmometer no longer. J Biol Chem 285:6134–6144
50. Nagy S, Paál M, Kõszegi T, Ludany A, Kellermayer M (1998) ATP and integrity of human red blood cells. Physiol Chem Phys Med NMR 30:141–148
51. Planker M, Schnurr E, Schneider W (1983) Elevated ATP levels in the red cells of patients with renal failure. Klin Wochenschr 61:709–713
52. Dale GL, Norenberg SL (1989) Time-dependent loss of adenosine 5'-monophosphate deaminase activity may explain elevated adenosine 5'-triphosphate levels in senescent erythrocytes. Blood 74:2157–2160
53. van Giezen JJ, Sidaway J, Glaves P, Kirk I, Björkman JA (2012) Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 17:164–172
54. Öhman J, Kudira R, Albinsson S, Olde B, Erlinge D (2012) Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun 418:754–758
55. Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D (2013) Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology 124:252–258
56. Ye Y, Birnbaum GD, Perez-Polo JR, Nanhwan MK, Nylander S, Birnbaum Y (2015) Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol Epub ahead of print 4/6/15
57. Swennen EL, Dagnelie PC, Van den Beucken T, Bast A (2008) Radioprotective effects of ATP in human blood ex vivo. Biochem Biophys Res Commun 367:383–387
58. Zhu H, Zennadi R, Xu BX, Eu JP, Torok JA, Telen MJ, McMahon TJ (2011) Impaired adenosine-5'-triphosphate release from red blood cells promotes their adhesion to endothelial cells: a mechanism of hypoxemia after transfusion. Crit Care Med 39:2478–2486
59. Leal Denis MF, Incicco JJ, Espelt MV, Verstraeten SV, Pignataro OP, Lazarowski ER, Schwarzbaum PJ (2013) Kinetics of extracellular ATP in mastoparan 7-activated human erythrocytes. Biochim Biophys Acta 1830:4692–4707
60. Deyrup IJ (1951) Release of adenine derivatives from mammalian erythrocytes following admixture of blood with strongly hypertonic solutions. Am J Physiol 167:749–755
61. Pessina GP, Bocci V, Paulesu L, Alessandrini C, Gerli R (1980) Sialocompounds-poor vesicles isolated from ATP-depleted human erythrocytes. J Submicrosc Cytol 12:311–314
62. Müller H, Schmidt U, Lutz HU (1981) On the mechanism of red blood cell shape change and release of spectrin-free vesicles. Acta Biol Med Ger 40:413–417
63. Bergfeld GR, Forrester T (1992) Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res 26:40–47
64. Ellsworth ML, Forrester T, Ellis CG, Dietrich HH (1995) The erythrocyte as a regulator of vascular tone. Am J Physiol 269:H2155–H2161
65. Sprague RS, Ellsworth ML, Detrich HH (2003) Nucleotide release and purinergic signaling in the vasculature driven by the red blood cell. Curr Top Membr 54:243–268
66. Sprague RS, Bowles EA, Achilleus D, Ellsworth ML (2011) Erythrocytes as controllers of perfusion distribution in the microvasculature of skeletal muscle. Acta Physiol (Oxf) 202:285–292
67. 2 supply within the microvasculature? Microcirculation 19:440–450
68. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ (1996) ATP: the red blood cell link to NO and local control of the pulmonary circulation. Am J Physiol 271:H2717–H2722
69. Price AK, Fischer DJ, Martin RS, Spence DM (2004) Deformation-induced release of ATP from erythrocytes in a poly(dimethylsiloxane)-based microchip with channels that mimic resistance vessels. Anal Chem 76:4849–4855
70. Moehlenbrock MJ, Price AK, Martin RS (2006) Use of microchip-based hydrodynamic focusing to measure the deformation-induced release of ATP from erythrocytes. Analyst 131:930–937
71. Wan J, Forsyth AM, Stone HA (2011) Red blood cell dynamics: from cell deformation to ATP release. Integr Biol (Camb) 3:972–981
72. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ (1998) Increases in perfusate flow rate stimulate ATP release from red blood cells in isolated rabbit lungs. Exp Clin Cardiol 3:73–77
73. Sprague RS, Ellsworth ML, Stephenson AH, Kleinhenz ME, Lonigro AJ (1998) Deformation-induced ATP release from red blood cells requires CFTR activity. Am J Physiol 275:H1726–H1732
74. Forsyth AM, Wan J, Owrutsky PD, Abkarian M, Stone HA (2011) Multiscale approach to link red blood cell dynamics, shear viscosity, and ATP release. Proc Natl Acad Sci U S A 108:10986–10991
75. Montalbetti N, Leal Denis MF, Pignataro OP, Kobatake E, Lazarowski ER, Schwarzbaum PJ (2011) Homeostasis of extracellular ATP in human erythrocytes. J Biol Chem 286:38397–38407
76. Qiu F, Wang J, Spray DC, Scemes E, Dahl G (2011) Two non-vesicular ATP release pathways in the mouse erythrocyte membrane. FEBS Lett 585:3430–3435
77. i is involved in a signal transduction pathway for ATP release from erythrocytes. Am J Physiol Heart Circ Physiol 286:H940–H945
78. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ (2001) Participation of cAMP in a signal-transduction pathway relating erythrocyte deformation to ATP release. Am J Physiol Cell Physiol 281:C1158–C1164
79. Sprague R, Bowles E, Stumpf M, Ricketts G, Freidman A, Hou WH, Stephenson A, Lonigro A (2005) Rabbit erythrocytes possess adenylyl cyclase type II that is activated by the heterotrimeric G proteins Gs and Gi. Pharmacol Rep 57(Suppl):222–228
80. Montalbetti N, Lazarowski E, Schwarzbaum P (2010) Human erythrocytes release ATP in a cyclic AMP-regulated manner. Purinergic Signalling 6:S73
81. 2 delivery mediated by hemoglobin oxygenation. Am J Physiol Heart Circ Physiol 280:H2833–H2839
82. Sridharan M, Sprague RS, Adderley SP, Bowles EA, Ellsworth ML, Stephenson AH (2010) Diamide decreases deformability of rabbit erythrocytes and attenuates low oxygen tension-induced ATP release. Exp Biol Med (Maywood) 235:1142–1148
83. Dietrich HH, Ellsworth ML, Sprague RS, Dacey RG Jr (2000) Red blood cell regulation of microvascular tone through adenosine triphosphate. Am J Physiol Heart Circ Physiol 278:H1294–H1298
84. Sove RJ, Ghonaim N, Goldman D, Ellis CG (2013) A computational model of a microfluidic device to measure the dynamics of oxygen-dependent ATP release from erythrocytes. PLoS One 8:e81537
85. Faris A, Spence DM (2008) Measuring the simultaneous effects of hypoxia and deformation on ATP release from erythrocytes. Analyst 133:678–682
86. Mairbäurl H, Ruppe FA, Bärtsch P (2013) Role of hemolysis in red cell adenosine triphosphate release in simulated exercise conditions in vitro. Med Sci Sports Exerc 45:1941–1947
87. Adderley SP, Sprague RS, Stephenson AH, Hanson MS (2010) Regulation of cAMP by phosphodiesterases in erythrocytes. Pharmacol Rep 62:475–482
88. Sridharan M, Bowles EA, Richards JP, Krantic M, Davis KL, Dietrich KA, Stephenson AH, Ellsworth ML, Sprague RS (2012) Prostacyclin receptor-mediated ATP release from erythrocytes requires the voltage-dependent anion channel. Am J Physiol Heart Circ Physiol 302:H553–H559
89. i. Am J Physiol Heart Circ Physiol 287:H748–H754
90. 2 tension-induced ATP release. Am J Physiol Heart Circ Physiol 304:H660–H666
91. Cole RH, Malavalli A, Vandegriff KD (2009) Erythrocytic ATP release in the presence of modified cell-free hemoglobin. Biophys Chem 144:119–122
92. Agalakova NI, Gusev GP (2012) Fluoride induces oxidative stress and ATP depletion in the rat erythrocytes in vitro. Environ Toxicol Pharmacol 34:334–337
93. Hanson MS, Ellsworth ML, Achilleus D, Stephenson AH, Bowles EA, Sridharan M, Adderley S, Sprague RS (2009) Insulin inhibits low oxygen-induced ATP release from human erythrocytes: implication for vascular control. Microcirculation 16:424–433
94. Hanson MS, Stephenson AH, Bowles EA, Sprague RS (2010) Insulin inhibits human erythrocyte cAMP accumulation and ATP release: role of phosphodiesterase 3 and phosphoinositide 3-kinase. Exp Biol Med (Maywood) 235:256–262
95. 13 receptors is a negative feedback pathway for ATP release from human red blood cells. Circ Res 96:189–196
96. Ellsworth ML, Chrzaszcz MA, O’Keefe E, Achilleus D, Bowles E, Sprague RS (2007) Caffeine enhances ATP release from erythrocytes: consequences for peripheral vascular perfusion. FASEB J 21:A479–A480
97. Rozier MD, Zata VJ, Ellsworth ML (2007) Lactate interferes with ATP release from red blood cells. Am J Physiol Heart Circ Physiol 292:H3038–H3042
98. Cao Z, Bell JB, Mohanty JG, Nagababu E, Rifkind JM (2009) Nitrite enhances RBC hypoxic ATP synthesis and the release of ATP into the vasculature: a new mechanism for nitrite-induced vasodilation. Am J Physiol Heart Circ Physiol 297:H1494–H1503
99. Garcia JI, Seabra AB, Kennedy R, English AM (2010) Nitrite and nitroglycerin induce rapid release of the vasodilator ATP from erythrocytes: Relevance to the chemical physiology of local vasodilation. J Inorg Biochem 104:289–296
100. Sprague RS, Hanson MS, Achilleus D, Bowles EA, Stephenson AH, Sridharan M, Adderley S, Procknow J, Ellsworth ML (2009) Rabbit erythrocytes release ATP and dilate skeletal muscle arterioles in the presence of reduced oxygen tension. Pharmacol Rep 61:183–190
101. Kalsi KK, González-Alonso J (2012) Temperature-dependent release of ATP from human erythrocytes: mechanism for the control of local tissue perfusion. Exp Physiol 97:419–432
102. Gov NS, Safran SA (2005) Red blood cell membrane fluctuations and shape controlled by ATP-induced cytoskeletal defects. Biophys J 88:1859–1874
103. Wan J, Ristenpart WD, Stone HA (2008) Dynamics of shear-induced ATP release from red blood cells. Proc Natl Acad Sci U S A 105:16432–16437
104. Thuet KM, Bowles EA, Ellsworth ML, Sprague RS, Stephenson AH (2011) The Rho kinase inhibitor Y-27632 increases erythrocyte deformability and low oxygen tension-induced ATP release. Am J Physiol Heart Circ Physiol 301:H1891–H1896
105. Raththagala M, Karunarathne W, Kryziniak M, McCracken J, Spence DM (2010) Hydroxyurea stimulates the release of ATP from rabbit erythrocytes through an increase in calcium and nitric oxide production. Eur J Pharmacol 645:32–38
106. Forsyth AM, Braunmüller S, Wan J, Franke T, Stone HA (2012) The effects of membrane cholesterol and simvastatin on red blood cell deformability and ATP release. Microvasc Res 83:347–351
107. Akatsu T, Tsukada K, Hishiki T, Suga-Numa K, Tanabe M, Shimazu M, Kitagawa Y, Yachie-Kinoshita A, Suematsu M (2010) T-state stabilization of hemoglobin by nitric oxide to form alpha-nitrosyl heme causes constitutive release of ATP from human erythrocytes. Adv Exp Med Biol 662:109–114
108. Kirby BS, Garcia LJ, Crecelius AR, Richards JC, Luckasen GJ, Larson DG, Dinenno FA (2012) Erythrocytes from older healthy humans fail to release ATP during hemoglobin deoxygenation. FASEB J 26:860.22
109. Adderley SP, Sridharan M, Bowles EA, Stephenson AH, Sprague RS, Ellsworth ML (2011) Inhibition of ATP release from erythrocytes: a role for EPACs and PKC. Microcirculation 18:128–135
110. Melhorn MI, Brodsky AS, Estanislau J, Khoory JA, Illigens B, Hamachi I, Kurishita Y, Fraser AD, Nicholson-Weller A, Dolmatova E, Duffy HS, Ghiran IC (2013) CR1-mediated ATP release by human red blood cells promotes CR1 clustering and modulates the immune transfer process. J Biol Chem 288:31139–31153
111. 2 content by rat aortic bodies. Exp Physiol 99:248–261
112. Lockwood SY, Erkal JL, Spence DM (2014) Endothelium-derived nitric oxide production is increased by ATP released from red blood cells incubated with hydroxyurea. Nitric Oxide 38:1–7
113. Akkaya C, Shumilina E, Bobballa D, Brand VB, Mahmud H, Lang F, Huber SM (2009) The Plasmodium falciparum-induced anion channel of human erythrocytes is an ATP-release pathway. Pflugers Arch 457:1035–1047
114. Levano-Garcia J, Dluzewski AR, Markus RP, Garcia CR (2010) Purinergic signalling is involved in the malaria parasite Plasmodium falciparum invasion to red blood cells. Purinergic Signal 6:365–372
115. Alvarez CL, Schachter J, de Sá Pinheiro AA, Silva LS, Verstraeten SV, Persechini PM, Schwarzbaum PJ (2014) Regulation of extracellular ATP in human erythrocytes infected with Plasmodium falciparum. PLoS One 9:e96216
116. Ayi K, Liles WC, Gros P, Kain KC (2009) Adenosine triphosphate depletion of erythrocytes simulates the phenotype associated with pyruvate kinase deficiency and confers protection against Plasmodium falciparum in vitro. J Infect Dis 200:1289–1299
117. Tanneur V, Duranton C, Brand VB, Sandu CD, Akkaya C, Kasinathan RS, Gachet C, Sluyter R, Barden JA, Wiley JS, Lang F, Huber SM (2006) Purinoceptors are involved in the induction of an osmolyte permeability in malaria-infected and oxidized human erythrocytes. FASEB J 20:133–135
118. Gati WP, Lin AN, Wang TI, Young JD, Paterson AR (1990) Parasite-induced processes for adenosine permeation in mouse erythrocytes infected with the malarial parasite Plasmodium yoelii. Biochem J 272:277–280
119. de Machado Salles É, Zago CA, da Borges Silva H, Mosig JM, Coutinho Silva R, Lima MR (2011) Role of ATP and P2X7 receptor in the CD4+ T cell response to blood-stage Paramecium chabaudi malaria. Purinergic Signalling 7:140
120. Huber SM (2012) Purinoceptor signaling in malaria-infected erythrocytes. Microbes Infect 14:779–786
121. Munksgaard PS, Vorup-Jensen T, Reinholdt J, Söderstrom CM, Poulsen K, Leipziger J, Praetorius HA, Skals M (2012) Leukotoxin from Aggregatibacter actinomycetemcomitans causes shrinkage and P2X receptor-dependent lysis of human erythrocytes. Cell Microbiol 14:1904–1920
122. Skals M, Jorgensen NR, Leipziger J, Praetorius HA (2009) α-Hemolysin from Escherichia coli uses endogenous amplification through P2X receptor activation to induce hemolysis. Proc Natl Acad Sci U S A 106:4030–4035
123. Skals MG, Leipziger J, Praetorius H (2013) E. coli α-haemolysin leads to ATP release and P2-dependent calcium influx in human erythrocytes. FASEB J 27:lb721
124. Skals M, Bjaelde RG, Reinholdt J, Poulsen K, Vad BS, Otzen DE, Leipziger J, Praetorius HA (2014) Bacterial RTX toxins allow acute ATP release from human erythrocytes directly through the toxin pore. J Biol Chem 289:19098–19109
125. Fagerberg SK, Skals M, Leipziger J, Praetorius HA (2013) P2X receptor-dependent erythrocyte damage by α-hemolysin from Escherichia coli triggers phagocytosis by THP-1 cells. Toxins (Basel) 5:472–487
126. Hejl JL, Skals M, Leipziger J, Praetorius HA (2013) P2X receptor stimulation amplifies complement-induced haemolysis. Pflugers Arch 465:529–541
127. Da Silva AS, Franca RT, Costa MM, Paim FC, Pimentel VC, Schmatz R, Jaques JA, Schetinger MR, Mazzanti CM, Tonin AA, Monteiro SG, Lopes ST (2013) Adenosine levels in serum and adenosine deaminase activity in blood cells of dogs infected by Rangelia vitalii. J Parasitol 99:1125–1128
128. Yeung PK, Seto D (2013) A study of the effect of isoproterenol on red blood cell concentrations of adenine nucleotides in a freely moving rat model in vivo. Cardiol Pharmacol 2:102
129. Sprague RS, Stephenson AH, Ellsworth ML, Keller C, Lonigro AJ (2001) Impaired release of ATP from red blood cells of humans with primary pulmonary hypertension. Exp Biol Med (Maywood) 226:434–439
130. Knebel SM, Elrick MM, Bowles EA, Zdanovec AK, Stephenson AH, Ellsworth ML, Sprague RS (2013) Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes. Exp Biol Med (Maywood) 238:1069–1074
131. i in erythrocytes of humans with type 2 diabetes is associated with impairment of both cAMP generation and ATP release. Diabetes 55:3588–3593
132. Sprague RS, Stephenson AH, Ellsworth ML (2007) Red not dead: signaling in and from erythrocytes. Trends Endocrinol Metab 18:350–355
133. Subasinghe W, Spence DM (2008) Simultaneous determination of cell aging and ATP release from erythrocytes and its implications in type 2 diabetes. Anal Chim Acta 618:227–233
134. 2-induced ATP release from erythrocytes of humans with type 2 diabetes: implication for vascular control. Am J Physiol Heart Circ Physiol 301:H2466–H2472
135. 2-induced ATP release from human erythrocytes. Am J Physiol Regul Integr Comp Physiol 305:R1331–R1336
136. 2-induced ATP release from erythrocytes of humans with Type 2 diabetes. Am J Physiol Regul Integr Comp Physiol 308:R411–R418
137. Zhang Y, Xia Y (2012) Adenosine signaling in normal and sickle erythrocytes and beyond. Microbes Infect 14:863–873
138. Zhang Y, Liu H, Sun K, Song A, Karmouty-Quintana H, Chen NY, Grenz A, Kellems RE, Idowu M, Juneja HS, Roach R, Eltzschig H, Blackburn MR, Xia Y (2013) Adenosine is a common factor regulating erythrocyte 2,3-bisphosphate induction in normal individuals at high altitude and in patients with sickle cell disease. Blood 122:952
139. Field JJ, Nathan DG, Linden J (2014) The role of adenosine signaling in sickle cell therapeutics. Hematol Oncol Clin North Am 28:287–299
140. Zhang Y, Dai Y, Wen J, Zhang W, Grenz A, Sun H, Tao L, Lu G, Alexander DC, Milburn MV, Carter-Dawson L, Lewis DE, Zhang W, Eltzschig HK, Kellems RE, Blackburn MR, Juneja HS, Xia Y (2011) Detrimental effects of adenosine signaling in sickle cell disease. Nat Med 17:79–86
141. Gladwin MT (2011) Adenosine receptor crossroads in sickle cell disease. Nat Med 17:38–40
142. Misiti F, Orsini F, Clementi ME, Masala D, Tellone E, Galtieri A, Giardina B (2008) Amyloid peptide inhibits ATP release from human erythrocytes. Biochem Cell Biol 86:501–508
143. Haslam RJ, Davidson MML, Lemmex BWG, Desjardins JV, McCarry BE (1979) Adenosine receptors of the blood platelet: interactions with adenylate cyclase. In: Baer HP, Drummond GI (eds) Physiological and regulatory functions of adenosine and adenine nucleotides. Raven Press, New York, pp 189–204
144. Agarwal KC (1987) Adenosine and platelet function. In: Stefanovich V, Okyayuz-Baklouti I (eds) Adenosine. VNU Science Press, The Netherlands, pp 107–124
145. Johnston-Cox HA, Ravid K (2011) Adenosine and blood platelets. Purinergic Signal 7:357–365
146. Skaer RJ (1975) Elemental composition of platelet dense bodies. Ciba Found Symp 35:239–259
147. Zucker MB (1980) The functioning of blood platelets. Sci Am 242:86–103
148. Da Prada M, Richards JG, Kettler R (1981) Amine storage organelles in platelets. In: Gordon JL (ed) Platelets in biology and pathology 2, research monographs in cell and tissue physiology. Elsevier, Amsterdam, pp 105–145
149. 1 receptors in platelet activation. Platelets 15:131–144
150. Mahaut-Smith MP, Jones S, Evans RJ (2011) The P2X1 receptor and platelet function. Purinergic Signal 7:341–356
151. 1 ion channel in platelet function. Platelets 21:153–166
152. Gachet C, Cazenave JP (1991) ADP induced blood platelet activation: a review. Nouv Rev Fr Hematol 33:347–358
153. Hourani SM, Cusack NJ (1991) Pharmacological receptors on blood platelets. Pharmacol Rev 43:243–298
154. 2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 16:179–181
155. Gachet C, Hechler B, Léon C, Vial C, Leray C, Ohlmann P, Cazenave JP (1997) Activation of ADP receptors and platelet function. Thromb Haemost 78:271–275
156. Mills DC (1996) ADP receptors on platelets. Thromb Haemost 76:835–856
157. Kunapuli SP (1998) Functional characterization of platelet ADP receptors. Platelets 9:343–351
158. Cattaneo M, Gachet C (2001) The platelet ADP receptors. Haematologica 86:346–348
159. Gachet C (2006) Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 46:277–300
160. Gachet C (2008) P2 receptors, platelet function and pharmacological implications. Thromb Haemost 99:466–472
161. Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF (2006) The platelet ATP and ADP receptors. Curr Pharm Des 12:859–875
162. Hechler B, Gachet C (2011) P2 receptors and platelet function. Purinergic Signal 7:293–303
163. Jacobson KA, Deflorian F, Mishra S, Costanzi S (2011) Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal 7:305–324
164. Packham MA, Rand ML (2011) Historical perspective on ADP-induced platelet activation. Purinergic Signal 7:283–292
165. Oh EY, Abraham T, Saad N, Rapp JH, Vastey FL, Balmir E (2012) A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert Opin Pharmacother 13:175–191
166. 12 receptor regulation. Biochem Soc Trans 41:225–230
167. 12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs 73:1681–1709
168. Sage SO, MacKenzie AB, Jenner S, Mahaut-Smith MP (1997) Purinoceptor-evoked calcium signalling in human platelets. Prostaglandins Leukot Essent Fatty Acids 57:435–438
169. Zimmermann H (1999) Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis. Nat Med 5:987–988
170. Yegutkin GG, Gonzalez-Alonso J (2007) Circulating ATP and ADP: important regulators of blood flow and platelet reactivity during exercise. Physiol News 68:31–33
171. Herbert JM, Savi P, Maffrand JP (1999) Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist. Eur Heart J 20:A31–A40
172. Kunapuli SP, Ding Z, Dorsam RT, Kim S, Murugappan S, Quinton TM (2003) ADP receptors - targets for developing antithrombotic agents. Curr Pharm Des 9:2303–2316
173. Boeynaems JM, van Giezen H, Savi P, Herbert JM (2005) P2Y receptor antagonists in thrombosis. Curr Opin Investig Drugs 6:275–282
174. Gachet C (2005) The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 108:180–192
175. Gachet C, Léon C, Hechler B (2006) The platelet P2 receptors in arterial thrombosis. Blood Cells Mol Dis 36:223–227
176. 12 inhibitors. Circulation 121:171–179
177. 12 receptor as a target of antithrombotic drugs. Purinergic Signal 7:325–332
178. Tello-Montoliu A, Jover E, Rivera J, Valdés M, Angiolillo DJ, Marín F (2012) New perspectives in antiplatelet therapy. Curr Med Chem 19:406–427
179. Gachet C, Hechler B (2013) The P2Y receptors and thrombosis. WIREs Membr Transp Signal 2:241–253
180. Nurden AT (2011) Platelets, inflammation and tissue regeneration. Thromb Haemost 105(Suppl 1):S13–S33
181. 12 receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal 8:609–619
182. Cattaneo M (2011) Molecular defects of the platelet P2 receptors. Purinergic Signal 7:333–339
183. Born GV (1956) Adenosinetriphosphate (ATP) in blood platelets. Biochem J 62:331
184. Born GV (1958) Changes in the distribution of phosphorus in platelet-rich plasma during clotting. Biochem J 68:695–704
185. Hellem AJ (1960) The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 12(Suppl):1–117
186. Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA (1961) Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 192:531–532
187. Born GV (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927–929
188. Agarwal KC, Parks RE Jr, Townsend LB (1979) Adenosine analogs and human platelets - II. Inhibition of ADP-induced aggregation by carbocyclic adenosine and imidazole-ring modified analogs. Significance of alterations in the nucleotide pools. Biochem Pharmacol 28:501–510
189. Born GV (1984) Platelets and blood vessels. J Cardiovasc Pharmacol 6(Suppl 4):S706–S713
190. Born GV, Cross MJ (1963) The aggregation of blood platelets. J Physiol 168:178–195
191. Salzman EW, Chambers DA, Neri LL (1966) Possible mechanism of aggregation of blood platelets by adenosine diphosphate. Nature 210:167–169
192. Ardlie NG, Packham MA, Mustard JF (1970) Adenosine diphosphate-induced platelet aggregation in suspensions of washed rabbit platelets. Br J Haematol 19:7–17
193. Stafford NP, Pink AE, White AE, Glenn JR, Heptinstall S (2003) Mechanisms involved in adenosine triphosphate--induced platelet aggregation in whole blood. Arterioscler Thromb Vasc Biol 23:1928–1933
194. Macfarlane DE, Mills DC (1975) The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation. Blood 46:309–320
195. Wang TY, Hussey CV, Garancis JC (1977) Inhibitory effects of ATP on platelet aggregation: cation interaction and shape change. Ann Clin Lab Sci 7:88–92
196. Cooper DM, Rodbell M (1979) ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature 282:517–518
197. Fujimoto T, Hawiger J (1982) Adenosine diphosphate induces binding of von Willebrand factor to human platelets. Nature 297:154–156
198. Cusack NJ, Hourani SM (1982) Specific but noncompetitive inhibition by 2-alkylthio analogues of adenosine 5'-monophosphate and adenosine 5'-triphosphate of human platelet aggregation induced by adenosine 5'-diphosphate. Br J Pharmacol 75:397–400
199. Kauffenstein G, Hechler B, Cazenave JP, Gachet C (2004) Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J Thromb Haemost 2:1980–1988
200. 12 receptors. Thromb Res 132:548–557
201. Hallam TJ, Rink TJ (1985) Responses to adenosine diphosphate in human platelets loaded with the fluorescent calcium indicator quin2. J Physiol 368:131–146
202. Vanags DM, Rodgers SE, Duncan EM, Lloyd JV, Bochner F (1992) Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. Br J Pharmacol 106:917–923
203. Zamecnik PC, Kim B, Gao MJ, Taylor G, Blackburn GM (1992) Analogues of diadenosine 5',5'''-P1, P4-tetraphosphate (Ap4A) as potential anti-platelet-aggregation agents. Proc Natl Acad Sci U S A 89:2370–2373
204. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR (1993) Aspirin does not inhibit adenosine diphosphate-induced platelet α-granule release. Blood 82:505–512
205. 2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate. Br J Pharmacol 105:453–457
206. 2T-purinoceptors on human blood platelets. Br J Pharmacol 108:728–733
207. Hourani SMO, Welford LA, Cusack NJ (1996) Effects of 2-methylthioadenosine 5'β,γ-methylenetriphosphonate and 2-ethylthioadenosine 5'-monophosphate on human platelet activation induced by adenosine 5'-diphosphate. Drug Dev Res 38:12–23
208. 2T-purinoceptors. Br J Pharmacol 113:1057–1063
209. 2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. Br J Pharmacol 115:1110–1116
210. i2 proteins. Biochem J 312:775–779
211. 3H]PSB-0413. Purinergic Signal 9:59–66
212. Anderson GM, Hall LM, Horne WC, Yang JX (1996) Adenosine diphosphate inhibits the serotonin transporter. Biochim Biophys Acta 1283:14–20
213. Thomsen H, Schmidtke E (1997) Stimulation of postmortem platelets with adenosine-5-diphosphate and epinephrine. Forensic Sci Int 89:47–55
214. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 403:26–30
215. 1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol 53:727–733
216. Jantzen HM, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds EE, Conley PB (1999) Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb Haemost 81:111–117
217. Jin J, Daniel JL, Kunapuli SP (1998) Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273:2030–2034
218. Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM (1998) Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 422:291–295
219. 1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood 92:152–159
220. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP (1998) Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 273:2024–2029
221. Geiger J, Hönig-Liedl P, Schanzenbächer P, Walter U (1998) Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol 351:235–246
222. 2X1 purinoceptor expressed on human platelets. Biochem Biophys Res Commun 242:525–528
223. 1 receptors and of platelet aggregation. Biochem Biophys Res Commun 256:94–97
224. 2T receptors. Br J Pharmacol 129:275–282
225. 12, an important drug target in platelets. Trends Pharmacol Sci 22:388–391
226. Hollopeter G, Jantzen H-M, Vincent D, Li G, England L, Ramakrishnan V, Yang R-B, Nurden P, Nurden A, Julius D, Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202–207
227. Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B, Laz TM, Palmer K, Bayne M, Monsma FJ Jr (2001) ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 276:8608–8615
228. 1 is required to inhibit platelet aggregation in whole blood under flow. Blood 98:3340–3345
229. Gear AR, Suttitanamongkol S, Viisoreanu D, Polanowska-Grabowska RK, Raha S, Camerini D (2001) Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood 97:937–945
230. 1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented. J Thromb Haemost 2:969–977
231. 12) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibα induced by conditions of high shear rate. Circulation 105:2531–2536
232. Wang L, Östberg O, Wihlborg AK, Brogren H, Jern S, Erlinge D (2003) Quantification of ADP and ATP receptor expression in human platelets. J Thromb Haemost 1:330–336
233. 3 and ADP receptors. Blood 99:193–198
234. 12 play a role in controlling shape change in human platelets. Platelets 14:15–20
235. Nylander S, Mattsson C, Ramstrom S, Lindahl TL (2003) The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation. Thromb Res 111:65–73
236. 12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol 142:1325–1331
237. 12 gene sequence variations in healthy subjects. Circulation 108:989–995
238. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ (2005) Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 25:252–257
239. Hetherington SL, Lodwick D, Goodall AH, Samani NJ (2005) Molecular basis for platelet hyper-reactivity to adenosine diphosphate (ADP) associated with the platelet P2Y1 receptor 1622 G allele. Heart 91:A60
240. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A, Kastrati A (2005) P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 16:199–204
241. 12 locus, is not associated with acute myocardial infarction. PLoS One 3:e1462
242. 12 receptor. Eur J Pharmacol 644:10–16
243. 12 receptor-mediated platelet aggregation. Thromb Haemost 108:119–132
244. 1 receptor. Biochem Pharmacol 68:1995–2002
245. 12 receptors at the level of calcium signaling in human platelets. Blood 104:1745–1752
246. Baurand A, Eckly A, Hechler B, Kauffenstein G, Galzi JL, Cazenave JP, Lén C, Gachet C (2005) Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol 67:721–733
247. 12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 105:3552–3560
248. Kanamarlapudi V, Owens SE, Saha K, Pope RJ, Mundell SJ (2012) ARF6-dependent regulation of P2Y receptor traffic and function in human platelets. PLoS One 7:e43532
249. Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C (1999) A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 94:4156–4165
250. 3-initiated signaling cross-talks. J Biomed Sci 12:937–948
251. 3 activation: association with Rap1B activation. J Thromb Haemost 4:1379–1387
252. 12 receptor variant associated with bleeding diathesis. Blood 125:1006–1013
253. Nicholas RA (2015) Insights into platelet P2Y12 receptor activation. Blood 125:893–895
254. 12 potentiates platelet shape change by a Rho kinase-dependent mechanism. Platelets 16:415–429
255. Frelinger AL III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113:2888–2896
256. 1. Biochem J 398:339–343
257. Moore DJ, Murdock PR, Watson JM, Faull RL, Waldvogel HJ, Szekeres PG, Wilson S, Freeman KB, Emson PC (2003) GPR105, a novel Gi/o-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function. Brain Res Mol Brain Res 118:10–23
258. 3 receptor. Thromb Haemost 100:261–270
259. 12-receptor. Biochem Pharmacol 76:1201–1213
260. 125I]MRS2500). Pharmacol Res 62:344–351
261. Fredman G, Van Dyke TE, Serhan CN (2010) Resolvin E1 regulates ASP activation of human platelets. Arterioscler Thromb Vasc Biol 30:2005–2013
262. Enomoto Y, Adachi S, Doi T, Natsume H, Kato K, Matsushima-Nishiwaki R, Akamatsu S, Tokuda H, Yoshimura S, Otsuka T, Ogura S, Kozawa O, Iwama T (2011) cAMP regulates ADP-induced HSP27 phosphorylation in human platelets. Int J Mol Med 27:695–700
263. 12 receptor-mediated amplification of platelet aggregation. Thromb Res 131:325–332
264. 12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 5:577–582
265. 12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A 110:15782–15787
266. Castellino FJ, Chapman MP, Donahue DL, Thomas S, Moore EE, Wohlauer MV, Fritz B, Yount R, Ploplis V, Davis P, Evans E, Walsh M (2014) Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats. J Trauma Acute Care Surg 76:1169–1176
267. 2 purinoceptors with unique properties modulates the function of human platelets. Biochim Biophys Acta 1177:199–207
268. 2T purinoceptors in human platelets. J Biol Chem 271:2879–2881
269. Savi P, Bornia J, Salel V, Delfaud M, Herbert JM (1997) Characterization of P2x1 purinoreceptors on rat platelets: effect of clopidogrel. Br J Haematol 98:880–886
270. 1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 78:1500–1504
271. 1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes. Blood 91:3172–3181
272. 1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression. J Biol Chem 273:11544–11547
273. Takano S, Kimura J, Matsuoka I, Ono T (1999) No requirement of P2X1 purinoceptors for platelet aggregation. Eur J Pharmacol 372:305–309
274. 1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 131:108–114
275. 2X1 receptor is preferentially activated by adenosine diphosphate in platelets and megakaryocytic cells. Blood 98:100–107
276. 1 ion channel. Thromb Haemost 86:1338–1339
277. Rolf MG, Brearley CA, Mahaut-Smith MP (2001) Platelet shape change evoked by selective activation of P2X1 purinoceptors with α, β-methylene ATP. Thromb Haemost 85:303–308
278. 1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 86:1264–1271
279. 1 knockout mice. 7th Int Symp on Adenosine and Adenine Nucleotides 79
280. 1 receptor function in murine megakaryocytes and human platelets reveals synergy with P2Y receptors. Br J Pharmacol 135:363–372
281. 1 cation channel in thrombosis of small arteries in vivo. J Exp Med 198:661–667
282. 1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 101:3969–3976
283. 1 receptors supports a role for ATP during hemostasis and thrombosis. Blood 102:3646–3651
284. Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C (2005) Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis -benzene-1,3-disulfonic acid octasodium salt]. J Pharmacol Exp Ther 314:232–243
285. 2+-calmodulin and myosin light chain kinase activation. J Biol Chem 279:26266–26273
286. 2+ responses of human platelets. Thromb Haemost 94:37–40
287. 1 receptors in human platelets with potency in the low nanomolar range. Naunyn Schmiedeberg’s Arch Pharmacol 372:1–13
288. 1 receptors to disruption of lipid rafts. Biochem Biophys Res Commun 343:415–419
289. 2+ in the human platelet. J Thromb Haemost 5:910–917
290. Karunarathne W, Ku CJ, Spence DM (2009) The dual nature of extracellular ATP as a concentration-dependent platelet P2X1 agonist and antagonist. Integr Biol (Camb) 1:655–663
291. 1 receptors. Thromb Res 125:159–165
292. 2+ signalling and platelet count. J Physiol 588:1399–1406
293. Lalo U, Jones S, Roberts JA, Mahaut-Smith MP, Evans RJ (2012) Heat shock protein 90 inhibitors reduce trafficking of ATP-gated P2X1 receptors and human platelet responsiveness. J Biol Chem 287:32747–32754
294. Born GV, Cross MJ (1962) Inhibition of the aggregation of blood platelets by substances related to adenosine diphosphate. J Physiol 166:29P–30P
295. Haslam RJ, Rosson GM (1975) Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 11:528–544
296. Cusack NJ, Hickman ME, Born GV (1979) Effects of D- and L- enantiomers of adenosine, AMP and ADP and their 2-chloro- and 2-azido- analogues on human platelets. Proc R Soc Lond B Biol Sci 206:139–144
297. Jakobs KH, Saur W, Johnson RA (1979) Regulation of platelet adenylate cyclase by adenosine. Biochim Biophys Acta 583:409–421
298. Cusack NJ, Born GV (1976) Inhibition of adenosine deaminase and of platelet aggregation by 2-azidoadenosine, a photolysable analogue of adenosine. Proc R Soc Lond B Biol Sci 193:307–311
299. Doni MG (1981) Adenosine uptake and deamination by blood platelets in different mammalian species. Haemostasis 10:79–88
300. 1 acid glycoprotein and its significance for the inhibition of adenosine uptake. J Clin Invest 60:936–943
301. Dawicki DD, Agarwal KC, Parks RE Jr (1986) Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233. Thromb Res 43:161–175
302. Bult H, Fret HR, Jordaens FH, Herman AG (1991) Dipyridamole potentiates platelet inhibition by nitric oxide. Thromb Haemost 66:343–349
303. Cusack NJ, Hourani SM (1981) 5'-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation. Br J Pharmacol 72:443–447
304. 3H]amine congener of 1,3-dipropyl-8-phenylxanthine. A new radioligand for A2 adenosine receptors of human platelets. FEBS Lett 199:269–274
305. 2) responsiveness of platelets. Br J Pharmacol 90:501–510
306. Dionisotti S, Zocchi C, Varani K, Borea PA, Ongini E (1992) Effects of adenosine derivatives on human and rabbit platelet aggregation. Correlation of adenosine receptor affinities and antiaggregatory activity. Naunyn Schmiedebergs Arch Pharmacol 346:673–676
307. Cristalli G, Vittori S, Thompson RD, Padgett WL, Shi D, Daly JW, Olsson RA (1994) Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn Schmiedebergs Arch Pharmacol 349:644–650
308. 3H]-CGS 21680 binding. Br J Pharmacol 117:1693–1701
309. 2A adenosine receptors in human peripheral blood cells. Br J Pharmacol 129:2–11
310. Grenegård M, Gustafsson MC, Andersson RG, Bengtsson T (1996) Synergistic inhibition of thrombin-induced platelet aggregation by the novel nitric oxide-donor GEA 3175 and adenosine. Br J Pharmacol 118:2140–2144
311. 2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. Thromb Res 121:689–698
312. Hart ML, Köhler D, Eckle T, Kloor D, Stahl GL, Eltzschig HK (2008) Direct treatment of mouse or human blood with soluble 5'-nucleotidase inhibits platelet aggregation. Arterioscler Thromb Vasc Biol 28:1477–1483
313. Amisten S, Braun OÖ, Bengtsson A, Erlinge D (2008) Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 122:47–57
314. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K (2010) A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 8:817–827
315. 12 antagonist. Arterioscler Thromb Vasc Biol 31:416–422
316. Kim K, Lim KM, Shin HJ, Seo DB, Noh JY, Kang S, Chung HY, Shin S, Chung JH, Bae ON (2013) Inhibitory effects of black soybean on platelet activation mediated through its active component of adenosine. Thromb Res 131:254–261
317. Beigi R, Kobatake E, Aizawa M, Dubyak GR (1999) Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am J Physiol 276:C267–C278
318. Cattaneo M (2009) Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 35:158–167
319. Pai M, Wang G, Moffat KA, Liu Y, Seecharan J, Webert K, Heddle N, Hayward C (2011) Diagnostic usefulness of a lumi-aggregometer adenosine triphosphate release assay for the assessment of platelet function disorders. Am J Clin Pathol 136:350–358
320. Hayward CP, Moffat KA, Castilloux JF, Liu Y, Seecharan J, Tasneem S, Carlino S, Cormier A, Rivard GE (2012) Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder. Thromb Haemost 107:726–734
321. von Papen M, Gambaryan S, Schütz C, Geiger J (2013) Determination of ATP and ADP secretion from human and mouse platelets by an HPLC assay. Transfus Med Hemother 40:109–116
322. Da Prada M, Lorez HP, Richards JG (1982) Platelet granules. In: Poisner AM, Trifaro JM (eds) The secretory granule. Elsevier Biomedical, Amsterdam, pp 279–316
323. Hiasa M, Togawa N, Miyaji T, Omote H, Yamamoto A, Moriyama Y (2014) Essential role of vesicular nucleotide transporter in vesicular storage and release of nucleotides in platelets. Physiol Rep 2:e12034
324. Barradas MA, Mikhailidis DP, Dandona P (1990) ADPase activity in human maternal and cord blood: possible evidence for a placenta-specific vascular protective mechanism. Int J Gynaecol Obstet 31:15–20
325. Beukers MW, Pirovano IM, van Weert A, Kerkhof CJ, IJzerman AP, Soudijn W (1993) Characterization of ecto-ATPase on human blood cells. A physiological role in platelet aggregation? Biochem Pharmacol 46:1959–1966
326. Frassetto SS, Dias RD, Sarkis JJ (1993) Characterization of an ATP diphosphohydrolase activity (APYRASE, EC 3.6.1.5) in rat blood platelets. Mol Cell Biochem 129:47–55
327. Frassetto SS, Dias RD, Sarkis JJ (1995) Inhibition and kinetic alterations by excess free ATP and ADP of the ATP diphosphohydrolase activity (EC 3.6.1.5) from rat blood platelets. Biochem Mol Biol Int 35:499–506
328. Pilla C, Emanuelli T, Frassetto SS, Battastini AM, Dias RD, Sarkis JJ (1996) ATP diphosphohydrolase activity (apyrase, EC 3.6.1.5) in human blood platelets. Platelets 7:225–230
329. Koziak K, Séevigny J, Robson SC, Siegel JB, Kaczmarek E (1999) Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thromb Haemost 82:1538–1544
330. Atkinson B, Dwyer K, Enjyoji K, Robson SC (2006) Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: potential as therapeutic targets. Blood Cells Mol Dis 36:217–222
331. Birk AV, Broekman MJ, Gladek EM, Robertson HD, Drosopoulos JH, Marcus AJ, Szeto HH (2002) Role of extracellular ATP metabolism in regulation of platelet reactivity. J Lab Clin Med 140:166–175
332. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R (2003) Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost 1:2497–2509
333. Buffon A, Ribeiro VB, Fürstenau CR, Battastini AM, Sarkis JJ (2004) Acetylsalicylic acid inhibits ATP diphosphohydrolase activity by platelets from adult rats. Clin Chim Acta 349:53–60
334. Fürstenau CR, Spier AP, Rücker B, Luisa Berti S, Battastini AM, Sarkis JJ (2004) The effect of ebselen on adenine nucleotide hydrolysis by platelets from adult rats. Chem Biol Interact 148:93–99
335. 1 receptor inhibition and soluble CD39 administration as novel approaches to widen the cardiovascular therapeutic window. Trends Cardiovasc Med 19:1–5
336. 2+ modulates ADP-evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y receptor activation. Br J Haematol 153:83–91
337. Pochmann D, Bohmer AE, Nejar Bruno A, Sarkis JJ (2005) Ecto-hydrolysis of adenine nucleotides in rat blood platelets are altered by ovariectomy. Platelets 16:334–339
338. Mundell SJ, Jones ML, Hardy AR, Barton JF, Beaucourt SM, Conley PB, Poole AW (2006) Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol 70:1132–1142
339. Cauwenberghs S, Feijge MA, Hageman G, Hoylaerts M, Akkerman JW, Curvers J, Heemskerk JW (2006) Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation. Transfusion 46:1018–1028
340. Leal CA, Schetinger MR, Leal DB, Bauchspiess K, Schrekker CM, Maldonado PA, Morsch VM, da Silva JE (2007) NTPDase and 5'-nucleotidase activities in platelets of human pregnants with a normal or high risk for thrombosis. Mol Cell Biochem 304:325–330
341. Yegutkin GG, Samburski SS, Mortensen SP, Jalkanen S, Gonzélez-Alonso J (2007) Intravascular ADP and soluble nucleotidases contribute to acute prothrombotic state during vigorous exercise in humans. J Physiol 579:553–564
342. Cook JJ, Sitko GR, Holahan MA, Stranieri MT, Glass JD, Askew BC, McIntyre CJ, Claremon DA, Baldwin JJ, Hartman GD, Gould RJ, Lynch JJ Jr (1997) Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation. J Pharmacol Exp Ther 281:677–689
343. 2T receptor: a novel approach to antithrombotic therapy. J Med Chem 42:213–220
344. 1 receptor-null mice. J Clin Invest 104:1731–1737
345. Steering Committee CAPRIE (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 348:1329–1339
346. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502
347. Weber AA, Reimann S, Schrör K (1999) Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 126:415–420
348. AC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 19:2007–2011
349. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, Maffrand JP (1992) Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 44:527–532
350. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F (2007) The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite. J Thromb Haemost 5:1545–1551
351. Angiolillo DJ, Ferreiro JL (2010) Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev Esp Cardiol 63:60–76
352. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, Lachno DR, Salazar D, Winters KJ (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–2436
353. 12-ADP receptor gene. Int J Cardiol 133:341–345
354. Sun D, McNicol A, James AA, Peng Z (2006) Expression of functional recombinant mosquito salivary apyrase: a potential therapeutic platelet aggregation inhibitor. Platelets 17:178–184
355. 12 ADP-receptor antagonist, INS50589. Platelets 18:346–356
356. 12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb Haemost 97:847–855
357. 12 receptor. J Pharmacol Exp Ther 331:648–655
358. 12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 17:6013–6018
359. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De SS, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015
360. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057
361. 12. Purinergic Signal 3:195–201
362. 1 antagonists as novel antiplatelet agents. Bioorg Med Chem Lett 23:4206–4209
363. Obergan TY, Lyapina LA, Pastorova VE (2007) Antithrombotic activity of heparin-ATP complex. Bull Exp Biol Med 143:299–301
364. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW (2010) Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 8:37–42
365. 12 receptor for adenosine diphosphate. Thromb Haemost 105(Suppl 1):S67–S74
366. 12 receptor independent pathway. Blood 122:2309
367. Kastalli S, El AS, Zaiem A, Ben Abdallah H, Daghfous R (2010) Fatal liver injury associated with clopidogrel. Fundam Clin Pharmacol 24:433–435
368. Belchikov YG, Koenig SJ, Dipasquale EM (2013) Potential role of endogenous adenosine in ticagrelor-induced dyspnea. Pharmacotherapy 33:882–887
369. 12 antagonism. J Thromb Haemost 11:1867–1876
370. Michelson AD (2011) Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program 2011:62–69
371. Winchester DE, Brearley WD, Wen X, Park KE, Bavry AA (2012) Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines. Clin Cardiol 35:93–100
372. 12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv 6:1111–1128
373. Coimbra LS, Steffens JP, Rossa C Jr, Graves DT, Spolidorio LC (2014) Clopidogrel enhances periodontal repair in rats through decreased inflammation. J Clin Periodontol 41:295–302
374. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol 58:e44–122
375. Tello-Montoliu A, Thano E, Rollini F, Patel R, Wilson RE, Müniz-Lozano A, Franchi F, Darlington A, Desai B, Guzman LA, Bass TA, Angiolillo DJ (2013) Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation. Thromb Haemost 110:777–784
376. Giachini FR, Leite R, Osmond DA, Lima VV, Inscho EW, Webb RC, Tostes RC (2014) Anti-platelet therapy with clopidogrel prevents endothelial dysfunction and vascular remodeling in aortas from hypertensive rats. PLoS One 9:e91890
377. 12 receptor in complex with an antithrombotic drug. Nature 509:115–118
378. Leven RM, Nachmias VT (1982) Cultured megakaryocytes: changes in the cytoskeleton after ADP-induced spreading. J Cell Biol 92:313–323
379. Leven RM, Mullikin WH, Nachmias VT (1983) Role of sodium in ADP- and thrombin-induced megakaryocyte spreading. J Cell Biol 96:1234–1240
380. 2+-dependent potassium conductance. J Physiol 431:207–224
381. Miller JL (1983) Characterization of the megakaryocyte secretory response: studies of continuously monitored release of endogenous ATP. Blood 61:967–972
382. +-current oscillation in rat megakaryocytes. Biochem J 295:317–320
383. 2+ oscillation. Br J Pharmacol 112:349–351
384. Uneyama H, Uneyama C, Ebihara S, Akaike N (1994) Suramin and reactive blue 2 are antagonists for a newly identified purinoceptor on rat megakaryocyte. Br J Pharmacol 111:245–249
385. Somasundaram B, Mahaut-Smith MP (1994) Three cation influx currents activated by purinergic receptor stimulation in rat megakaryocytes. J Physiol 480:225–231
386. 2U purinoceptors in human megakaryocytic Dami cells. Blood 83:1258–1267
387. 2U purinoceptors on the human megakaryoblastic cell line, Meg-01. Characterization by functional and binding studies. Nouv Rev Fr Hematol 37:231–240
388. Kawa K (1996) ADP-induced rapid inward currents through Ca(2+)-permeable cation channels in mouse, rat and guinea-pig megakaryocytes: a patch-clamp study. J Physiol 495:339–352
389. 2T ADP receptor in Xenopus oocytes injected with megakaryocyte (CMK 11-5) RNA. Arterioscler Thromb Vasc Biol 17:769–777
390. 1 receptors in mouse megakaryocytes. Thromb Res 119:343–353
391. Hechler B, Toselli P, Ravanat C, Gachet C, Ravid K (2001) Mpl ligand increases P2Y1 receptor gene expression in megakaryocytes with no concomitant change in platelet response to ADP. Mol Pharmacol 60:1112–1120
392. Gurung IS, Martinez-Pinna J, Mahaut-Smith MP (2008) Novel consequences of voltage-dependence to G-protein-coupled P2Y1 receptors. Br J Pharmacol 154:882–889
393. 2+ mobilization in the rat megakaryocyte. J Physiol 555:61–70
394. Zhao J, Ennion SJ (2006) Sp1/3 and NF-1 mediate basal transcription of the human P2X1 gene in megakaryoblastic MEG-01 cells. BMC Mol Biol 7:10
395. Young JP, Beckerman J, Vicini S, Myers A (2010) Acetylsalicylic acid enhances purinergic receptor-mediated outward currents in rat megakaryocytes. Am J Physiol Cell Physiol 298:C602–C610
396. Balduini A, Di Buduo CA, Malara A, Lecchi A, Rebuzzini P, Currao M, Pallotta I, Jakubowski JA, Cattaneo M (2012) Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes. Haematologica 97:1657–1665
397. Di Buduo C, Malara A, Pallotta I, Lecchi A, Balduini A, Cattaneo M (2013) The interaction of adenosine diphosphate with P2Y13 receptors in vitro proplatelet formation from human megakaryocytes. J Thromb Haemost 9:73
398. Burnstock G, Boeynaems J-M (2014) Purinergic signalling and immune cells. Purinergic Signalling 10:529–564
399. Nalos M, Huang S, Sluyter R, Khan A, Santner-Nanan B, Nanan R, McLean AS (2008) "Host tissue damage" signal ATP impairs IL-12 and IFNγ secretion in LPS stimulated whole human blood. Intensive Care Med 34:1891–1897
400. Stachon P, Hergeth SH, Anto Michel NM, Dufner B, Rodriguez AR, Hoppe N, Wolf DW, Bode CB, Idzko MI, Zirlik AZ (2013) Extracellular atp contributes to atherogenesis via purinergic receptors by inducing leukocyte recruitment in mice. Eur Heart J 34:442
401. De Pablo C, Orden S, Esplugues JV, Álvarez A (2013) ATP plays a role in leukocyte accumulation induced by ABC through its P2X7 receptors. Basic Clin Pharmacol Toxicol 113:18
402. Cabiati M, Caruso R, Verde A, Sabatino L, Morales MA, Del Ry S (2013) Transcriptomic profiling of the four adenosine receptors in human leukocytes of heart failure patients. Biomed Res Int 2013:569438
403. Kunapuli SP (1998) Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Trends Pharmacol Sci 19:391–394
404. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516